This article considers sample size determination for jointly testing a cause-specific hazard and the all-cause hazard for competing risks data. The cause-specific hazard and the all-cause hazard jointly characterize important study end points such as the disease-specific survival and overall survival, which are commonly used as coprimary end points in clinical trials. Specifically, we derive sample size calculation methods for 2-group comparisons based on an asymptotic chi-square joint test and a maximum joint test of the aforementioned quantities, taking into account censoring due to lost to follow-up as well as staggered entry and administrative censoring. We illustrate the application of the proposed methods using the Die Deutsche Diabetes Dialyse Studies clinical trial. An R package "powerCompRisk" has been developed and made available at the CRAN R library.
INTRODUCTION
In a clinical trial of a new treatment targeting a specific disease, the disease-specific survival (DSS), defined as time to death due to the disease, and overall survival (OS), defined as time to death due to all causes, are often used as coprimary end points for studying how the treatment works on the disease and on a patient's OS, respectively. In such applications, simultaneous inference on DSS and OS can be facilitated using a competing risks model under which death due to other causes is a competing risk that is potentially correlated to DSS. [1] [2] [3] [4] For convenience, we will refer death due to the disease of interest as cause 1 failure and death due to other causes as cause 2 failure. Then, the treatment effects on DSS and OS are characterized jointly by the cause 1 cause-specific hazard (CSH 1 ), the instantaneous risk of failure due to cause 1, and the all-cause hazard (ACH), the instantaneous risk of failure due to all causes. Among other methods, Li and Yang used piecewise exponential distribution to approximate arbitrary patient entry pattern and loss to follow-up distribution. Further discussion of this topic can be found in the previous literatures [9] [10] [11] [12] [13] [14] and the references therein. In the presence of competing risks, current sample size calculation methods are based on either a CSH alone 15, 16 or a subdistribution hazard alone. 17, 18 However, sample size calculation methods for joint 2-sample comparison of both a CSH and the ACH are not available.
The primary goal of the paper is to derive power analysis methods for simultaneous 2-sample testing of both CSH 1 and ACH for competing risks data. Specifically, in Section 2, we introduce a chi-square joint test and a maximum joint test for 2-group comparison of both CSH 1 and ACH, which were proposed in Li and Yang, 4 and derive their asymptotic properties under contiguous local alternatives. The asymptotic results are then used to develop an approximate sample size determination procedure for each of the joint test. Both 2-sided and 1-sided tests are considered. Our sample size calculation formulas will account for 2 different types of censoring, independent random censoring due to lost to follow-up and administrative censoring caused by staggered entry and end of the study. In Section 3, we present simulations to compare the sample sizes required by the 2 tests and evaluate their achieved power performance. In Section 4, we use the Die Deutsche Diabetes Dialyse Studies (4-D) clinical trial to provide a step-by-step demonstration of how to implement our methods in practice. Further remarks are given in Section 5. Technical proofs are deferred in the Appendix. An R package "powerCompRisk" implementing the proposed sample size calculation methods is available at the CRAN R library. 19 
SAMPLE SIZE CALCULATION FOR JOINT TESTS OF CSH 1 AND ACH

Joint tests of CSH 1 and ACH
For the reader's convenience, we first review the chi-square joint test and the maximum joint test of CSH 1 and ACH that were proposed in Li and Yang. 4 Suppose that there are 2 independent groups of subjects (1 for control and 2 for treatment). For subject i in group k, let T ik , D ik , and C ik denote its failure time, failure type, and censoring time, respectively, i = 1, … , n k , k = 1, 2. Let a 1 and a 2 = 1 − a 1 be the patient allocation proportions for groups 1 and 2, respectively. Let n = n 1 + n 2 denote the total sample size. Assume that within group k, {(T ik , D ik , C ik ), i = 1, … , n k } are independent and identically distributed and that the censoring time C ik is independent of the failure time T ik . Assume further that the 2 groups have the same censoring survival function S c (t) = P(C ik > t). For group k (k = 1, 2), one observes a right censored competing risks failure time data
Denote by S k (t) = P(T ik > t) the any-cause survival function for group k, k = 1, 2. For convenience, we assume hereafter that there are only 2 causes of failure and that cause 1 failure is of primary interest.
Consider the following joint hypothesis of CSH 1 and ACH:
where
is the CSH for cause j failure in group k ( j, k = 1, 2) and ·k (t) = 1k (t) + 2k (t) is the ACH for group k, k = 1, 2. The chi-square joint test statistic of Li and Yang 4 for (1) is defined as
} ,
is the number of observed failures due to cause j in group k by time t,
I{X ki ≥ t} is the number of patients in group k who are at risk just prior to time t, N · (t) =
,Σ is the estimated variance-covariance matrix of n −1/2 (U 11 , U ·1 ), 4 is the smallest t such that Y 1 (t)Y 2 (t) = 0, and W 1 (t) and W · (t) are 2 predictable weight functions that converge in probability to some deterministic functions w 1 (t) and w · (t) as n → ∞.
It has been shown by Li and Yang 4 that the limiting null distribution of X 2 n under H 0 is standard chi-square with 2 degrees of freedom. Thus, one rejects
, where 2 2, is the upper percentile of the standard 2 2 distribution. The maximum joint test statistic for (1) is defined as
where Z (n) N((0, 0) T , (1, 1, ) ). This allows one to obtain an approximate maximum test of H 0 based on M n .
Both the chi-square joint test and the maximum joint test aim to test the same joint null hypothesis (1) based on the same bivariate test statistic (U 11 , U ·1 ). However, they are based on different distance measures from (0,0). The chi-square joint test statistic is a Mahalanobis distance whereas the maximum joint test statistic is a maximum type distance. Consequently, they are sensitive to different alternative hypotheses as illustrated in the third paragraph of Section 3. Another distinction between the chi-square joint test and the maximum joint test is that the former applies only to 2-sided alternatives whereas the latter can be adapted to 1-sided alternatives.
In the next 2 sections, we will present sample size calculation procedures for the chi-square joint test and the maximum joint test. For the ease of interpretation and practical use, we will consider the simple case with W 1 (t) = W · (t) = 1 and assume the following commonly used proportional hazards alternatives
where ,
where D 1 = n × P 10 ( ) is the total number of cause 1 failures by time in the pooled sample across treatment groups and R = P 10 ( )∕P ·0 ( ) is the ratio of the cumulative incidence of failure due to cause 1 to cumulative incidence for failure due to all causes by time , which are approximately equal to the corresponding quantities in the pooled sample across treatment groups for large n under the local alternatives. Detailed information on derivation for Equation 5 is presented in Appendix A.2. Therefore, for a given type 1 error rate and a power 1 − , the required number of cause 1 failures in the pooled sample across treatment groups is approximately
where is solved from the following equation
( )),
with P 2 2 (x; k, ) being the noncentral chi-square cumulative distribution function with 2 degrees of freedom and noncentrality parameter .
In summary, the required number of cause 1 failures is determined by (6) by 3 parameters: (1) the CSH 1 ratio, exp(
, and (3) R, the ratio of cumulative incidence for failure due to cause 1 to cumulative incidence for failure due to any cause in the pooled sample across treatment groups. As illustrated later, these parameters can be obtained by specifying the cumulative incidence rate at a prespecified time for cause 1 failure and for any-cause failure in the control and experimental groups under the constant CSH assumption for each cause.
Required number of patients
We next discuss how to determine the required number of patients for a trial with staggered entry, administrative censoring, and loss to follow-up. Let f 1k (t) and P 1k (t) be the density and cumulative incidence function for cause 1 failure in group k, respectively, S c (t) be the survival function of the independent censoring due to lost to follow-up, f r (t) be the density function of the entry time T 0 , r be the length of the accrual period, and be the total length of the study period. Let Q 1k denote the probability of observing a cause 1 failure in groups k by the end of the study. Then, the totally number of patients required is given by
where for k = 1, 2,
In particular, if one further assumes constant CSH in each group k, uniform stagger entry over [0, r], and exponential lost to follow-up with constant hazard c , then for k = 1, 2,
In summary, the total number of patients needed to enroll in a study can be obtained from (8) , (10) , and (11) by specifying the following quantities: (1) the length of accrual time r, (2) the maximum follow-up time , (3) the patient proportion a 1 for group 1, (4) the hazard rate c for loss to follow-up, and (5) the CSH for cause 1 in group k 1k , k = 1, 2.
Sample size calculation for the maximum joint test
We now present an algorithm to calculate the required number of cause 1 failures and the required number of patients based on the maximum joint test defined in Equation 3.
Required number of cause 1 failures
Under the same local alternatives as in the previous section, it can be shown from part (b) of Theorem 1 in Appendix A.1 that (Z 11 , Z ·1 ) have approximately the following bivariate normal distribution
where D 1 = n × P 10 ( ) is the total number of cause 1 failures by time in the pooled sample across treatment groups and R = P 10 ( )∕P ·0 ( ) is the ratio of the cumulative incidence of failure due to cause 1 to cumulative incidence of failure due to all causes by time .
Hence, given a type 1 error rate and a type 2 error rate , the error equations
can be rewritten as
and
where C is the critical value of M n and f(x, y; 1 , 2 , ) denotes the bivariate normal density function with mean ( 1 , 2 ), variances (1,1), and correlation . In practice, one will first need to solve for C from (13) and then solve for D 1 from (14) using a numerical root finding routine. In summary, to obtain the required total number of cause 1 failuresD 1 for the maximum joint test as a root of (14) , one needs to input the following 3 parameters into Equations 13 and 14: (1) the CSH 1 ratio, exp( ⋆ 1 ) , (2) the ACH ratio, exp( ⋆ · ), and (3) R, the ratio of cumulative incidence of failure due to cause 1 to cumulative incidence of failure due to all causes in the pooled sample across treatment groups.
Required number of patients
The required number of patients for the maximum joint test is calculated exactly the same way as for the chi-square joint test as outlined in Section 2.2.2. In particular, if one assumes uniform staggered entry and constant hazards for all causes and loss to follow-up, then the total number of patients needed to enroll in a study is obtained from (8), (10) , and (11) by specifying the following quantities: (1) the length of accrual time r, (2) the maximum follow-up time , (3) the patient proportion a 1 for group 1, (4) the hazard rate c for loss to follow-up, and (5) the CSH for cause 1 in group k 1k , k = 1, 2.
Finally, we have implemented the above proposed procedures in an R package "powerCompRisk" with a detailed documentation and examples. 19 
SIMULATION STUDIES
We present 3 simulations to illustrate the operating characteristics of the proposed methods. Competing risks data are generated by using the CSH-driven method 20 that requires only specification of the CSH for each type of failure. We assume constant CSH in each group k, uniform stagger entry over [0, r], and exponential lost to follow-up with constant hazard c in all simulations.
In the first simulation, we compare the required sample sizes between the chi-square joint test and the maximum joint test under different effect size scenarios by varying the CSH 1 ratio and the ACH ratio, where in Table 1 , a hazard ratio of 1.2, 1.4, or 1.7 represents a small, medium, or large effect size. For each scenario, the implied CSH 2 ratio for the competing event as well as the cumulative incidence functions (by cause and group) is provided in Appendix B. We assume equal number of patients in the 2 groups (a 1 = a 2 = 0.5), a maximum follow-up time of = 10, the length of accrual period r = 1, and the rate of random censoring (attrition) due to lost to follow-up R c = 5%. The hazard rate for lost to follow-up is calculated by c =
. We set 11 = 0.3 and R = 0.8. With = 0.05 and power 1 − = 0.80, Table 1 summarizes Abbreviations: ACH, all-cause hazard; CSH 1 , cause 1 cause-specific hazard. Note: The cause-specific hazard for cause 1 in group 1 is 11 = 0.3, the ratio of cumulative incidence of failure due to cause 1 to all causes is R = 0.8, the length of recruitment period is r = 1, the length of the follow-up time is = 10, and the censoring rate due to loss of follow-up is R c = 0.05.
the required number of cause 1 failures and the required total number of patients for each of the 3 methods for various combinations of the CSH 1 ratio exp( It is observed from Table 1 that the chi-square joint test tends to require a fewer number of failures and patients among the 3 methods when the CSH 1 and ACH ratios are different. For instance, when the CSH 1 ratio is 1.2 and the ACH ratio is 1.4, the chi-square joint test requires 150 cause 1 failures and 204 patients, which are substantially lower than the 248 failures and 338 patients required by the maximum joint test. On the other hand, when the CSH 1 and ACH ratios are similar, the maximum joint test is observed to produce more sample size savings.
In the second simulation, we investigate the finite sample behavior of the proposed asymptotic sample size calculation methods by simulating their rejection powers under the scenarios considered in Table 1 . The observed powers are reported in Table 2 , which are close to the nominal power 0.80 across almost all cases considered.
In the third simulation, we explore how the attrition rate R c due to lost to follow-up, maximum follow-up time , and length of the accrual period r affect the sample size. Table 3 Table 1 . It is seen that the 3 parameters, r, , and R c , have no effect on the required number of cause 1 failures, but can impact the total number of required subjects significantly. As expected, the required number of patients (N) increases when the attrition rate due to lost to follow-up is higher, the maximum follow-up time ( ) is shorter, or the accrual period (r) is longer. In particular, when the follow-up time is shorter, the length of accrual period has a bigger impact on the sample size. For instance, for the chi-square test with attrition rate fixed at R c = 5% in Table 3 , increasing the length of accrual period from r = 1 to r = 2 would result in 396 − 346 = 50 more patients when = 8 as compared with 354 − 332 = 32 more patients when = 10. 
A REAL DATA EXAMPLE
We illustrate how to implement our method step-by-step using the 4-D trial. 21 The 4-D trial is a randomized, double-blinded, placebo-controlled trial to assess the efficacy of antihyperlipidemic treatment with atovastatin, in reducing occurrence of nonfatal myocardial infarction and cardiovascular mortality. There are 3 competing risks: nonfatal myocardial infarction (cause n), death due to cardiovascular disease (cause c), and death due to other causes (cause o).
As an illustration, we define the cause 1 failure of interest to be the composite event of either nonfatal myocardial infarction or death due to cardiovascular disease and cause 2 failure to be death due to other causes. Schulgen et al 16 illustrated nicely how to perform a power analysis for comparing the CSH 1 between the atovastatin and placeb groups. Here we demonstrate how to redesign this trial on the basis of a joint test of CSH 1 and ACH.
We first calculate the required number of cause 1 failures (nonfatal myocardial infection or cardiovascular death). As described in Section 2.2.1, the following quantities need to be specified: (1) CSH 1 ratio exp( ⋆ 1 ) , (2) ACH ratio exp( ⋆ · ), and (3) R, the ratio of cumulative incidence of failure due to cause 1 failure to all causes.
Let P c1 (t), P o1 (t), and P n1 (t) denote the probabilities of observing a cause c, cause o, and cause n failure, respectively, by time t in group 1. As in Schulgen et al, 16 we use information from a perspective cohort study from 1985 to 1994 in Germany. 22 It was reported that the 4-year any-cause mortality rate 22 was about 70%. About 60% of the deaths were due to cardiovascular diseases. 23 This implies that P c1 (4) = 0.7 * 0.6 = 0.42 and P o1 (4) = 0.7 * (1 − 0.6) = 0.21. In addition, a 10% 4-year rate of nonfatal myocardial infarction was anticipated among diabetes patients, which means that P n1 (4) = 0.10. Since the primary outcome is time to either the occurrence of nonfatal myocardial infarction or death due to cardiovascular disease, P 11 (4) = P c1 (4) + P n1 (4) = 0.52 and P ·1 (4) = P c1 (4) + P o1 (4) + P n1 (4) = 0.8.
To propose appropriate effect sizes, ⋆ 1 and ⋆ · , one needs to specify the anticipated 4-year cause 1 cumulative incidence P 12 (4) and any-cause cumulative incidence P ·2 (4) in group 2 (atovastatin). Schulgen et al 16 assumed that the intervention is efficacious if it reduces the 4-year occurrence of the cause 1 failure from 52% to 42%. We assume further that a reduction of the 4-year any-cause incidence from 80% to 70% is clinically significant. Assuming a constant CSH for each type of failure, then the above information can be converted to obtain all the required input parameters 11 We set type 1 error rate = 0.05, type 2 error rate = 0.2, and equal patient allocation proportions a 1 = a 2 = 0.5. Table 4 gives the required number of cause 1 events (nonfatal myocardial infarction or death due to cardiovascular disease) and the total number of patients under different combinations of the attrition rate, maximum follow-up time, and accrual period. It is observed that in this example, the design based on the maximum joint test would be more efficient with fewer required cause 1 events and total number of patients. This is consistent with the observation in our simulation study ( Table 1) that the maximum joint is more efficient when the CSH 1 and ACH ratios are similar.
DISCUSSION
Joint inference on a CSH and the ACH is often required for efficacy analysis of a clinical trial with competing risks data. We have developed power analysis tools for the design and planning of a clinical trial with competing risks for simultaneous 2-treatment comparisons of a CSH and the ACH based on either a chi-square joint test or a maximum joint test. Our simulations suggest that the chi-square joint test tends to requires fewer events and patients than the maximum joint test when the effect sizes for CSH 1 and ACH are different, whereas the maximum joint test tends to be more efficient when the effect sizes for CSH 1 and ACH are similar. In practice, it would be helpful to perform power analyses for both tests as illustrated in Section 4 with the 4-D trial.
Our method assumes the common proportional hazards alternatives that facilitates an easily implementable and interpretable sample size calculation method. We also incorporate random censoring due to lost to follow-up, staggered patient entry, and administrative censoring. In practice, one may encounter more complicated circumstances such as nonproportional hazards, treatment crossover, and more than 2 treatment arms, which may impact the required sample size as illustrated by Barthel et al. 24 There are also situations where there are several CSHs of importance. 25 Although it is possible to extend our methods to the abovementioned complex settings along the lines of this paper and the previous literatures, 4, 24, 25 the resulting formulas and their interpretations will be much more complicated. Further investigations are warrantied in future research.
APPENDIX A: GENERAL ASYMPTOTIC THEORY UNDER LOCAL ALTERNATIVES AND TECH-NICAL DERIVATIONS
A.1 General asymptotic theory under local alternatives
We establish the general asymptotic theory for the 2 joint tests described in Section 2.1 under some contiguous proportional hazards alternatives for cause 1 cause-specific hazard (CSH 1 ) and all-cause hazard (ACH), which provides a stepping stone for developing the sample size determination methods. The contiguous proportional hazards alternatives forCSH 1 and ACH can be formulated as
where either 1 ≠ 0 or · ≠ 0, 1 (t) and · (t) are prespecified and possibly time-varying functions and 10 (t) and ·0 (t) are unspecified baseline CSH and ACH, respectively. Gill 26 showed that a weighted log-rank test with a weight function converging to (t) gives the optimal power against the contiguous hazards alternative with a time-varying proportionality function (t). Therefore, we focus on weight functions w 1 (t) = 1 (t) and w · (t) = · (t). 
where Λ 10 (t) = ∫ t 0 10 (u)du, Λ ·0 (t) = ∫ t 0 ·0 (u)du, and P 10 (t) = ∫ t 0 0 (u)dΛ 10 (u) is the cumulative incidence for a cause 1 failure by time t, and P ·0 (t) = ∫ t 0 0 (u)dΛ ·0 (u) is the cumulative incidence for a failure due to all causes by time t. Furthermore, the covariance between n −1/2 U 11 and n −1/2 U ·1 under the contiguous alternative hypothesis is 
which converges in probability to 12 = ∫ 0 1 (t) · (t) a 1 a 2 1 (t) 2 (t) a 1 1 (t) + a 2 2 (t) dΛ 10 (t) = ∫ 0 1 (t) · (t)a 1 a 2 0 (t)dΛ 10 (t),
as n → ∞. Therefore, under the contiguous alternative hypothesis (A1), X 2 n has an asymptotic chi-square distribution with 2 degrees of freedom and noncentrality parameter = T Σ −1 . This proves part (a) of the theorem. (b). Let Z and correlation
